Growth Hormone Research · Peptide Comparisons

CJC-1295 with DAC vs without DAC: Pharmacokinetics, Research Applications, and Kinetic Differences

Topics covered: Molecular structure differences · Half-life and pharmacokinetics · GH pulse pattern implications for research · Kinetic consequences for study design · Where the literature uses each variant

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has attracted significant research interest for its ability to stimulate growth hormone (GH) secretion from the pituitary gland. Two distinct variants exist in the research catalogue: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29). These two compounds share the same core peptide sequence but differ fundamentally in their pharmacokinetic profiles — and that difference has profound implications for how each compound should be used in research protocols.

The confusion between these two variants is one of the most common sources of protocol errors in growth hormone research. Researchers who understand the pharmacokinetic distinction can design experiments that exploit the specific properties of each variant. Those who conflate the two — or who use one when the other is more appropriate — risk generating results that are difficult to interpret or that do not reflect the biology they intended to study.

This guide provides a rigorous comparison of CJC-1295 with DAC and CJC-1295 without DAC, covering their molecular structures, pharmacokinetic profiles, implications for GH pulse physiology, and practical guidance for selecting the appropriate variant for specific research objectives.

1. Molecular Structure: What the DAC Modification Does

Both CJC-1295 variants are based on the first 29 amino acids of endogenous GHRH (GHRH 1-29), with four amino acid substitutions that confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage — the primary enzyme responsible for rapid degradation of native GHRH in plasma. These substitutions are: Ala2→D-Ala (DPP-IV resistance), Asn8→Gln, Gly15→Ala and Met27→Leu (structural stability). The resulting compound — CJC-1295 without DAC, also called Modified GRF 1-29 — has a half-life of approximately 30 minutes in vivo, compared to less than 2 minutes for native GHRH.

CJC-1295 with DAC adds a further modification: a Drug Affinity Complex (DAC) technology that involves the addition of a lysine residue with a maleimidoproprionic acid (MPA) linker at position 29. This linker enables the peptide to form a covalent bond with the cysteine-34 residue of circulating albumin — the most abundant plasma protein. Once bound to albumin, the peptide is protected from proteolytic degradation and renal clearance, dramatically extending its half-life to approximately 6–8 days in rodents and an estimated 8–10 days in primates.

The DAC modification does not alter the peptide’s binding affinity for the GHRH receptor or its intrinsic ability to stimulate GH secretion — it solely affects pharmacokinetics. The same GHRH receptor agonist activity is present in both variants; the difference is entirely in how long the compound remains active in the system.

2. Pharmacokinetics: Half-Life and GH Release Patterns

3. GH Pulse Physiology: Why It Matters for Research

Understanding the significance of GH pulse physiology is essential for selecting the correct CJC-1295 variant. Growth hormone is not secreted continuously — it is released in discrete pulses, primarily during slow-wave sleep and in response to exercise, fasting, and other physiological stimuli. These pulses are generated by the alternating activity of two hypothalamic hormones: GHRH (which stimulates GH release) and somatostatin (which inhibits it). The pulsatile pattern of GH secretion is not merely an incidental feature of the system — it is functionally important.

Many of the downstream effects of GH — including anabolic effects on muscle and bone, lipolytic effects on adipose tissue, and IGF-1 production in the liver — are differentially regulated by pulsatile versus continuous GH exposure. Pulsatile GH exposure is more effective at stimulating linear growth and IGF-1 production than equivalent continuous exposure. This is because pulsatile GH maintains the sensitivity of GH receptors in target tissues, whereas continuous exposure leads to receptor downregulation.

This physiological context is critical for research design. CJC-1295 without DAC, with its 30-minute half-life, produces a transient GH pulse that closely mimics the physiological pattern. CJC-1295 with DAC, by maintaining continuous GHRH receptor stimulation over days, produces a sustained GH elevation that is pharmacologically distinct from the physiological pattern — and that partially overrides the somatostatin feedback mechanism that normally terminates GH pulses.

4. Where the Literature Uses Each Variant

CJC-1295 without DAC (Mod GRF 1-29) in the Literature

The short-acting variant appears in the published literature where the study design involves:

• Pulsatile GH stimulation: Studies examining the effects of physiologically patterned GH pulses on target tissues, receptor dynamics, or downstream signalling pathways.
• Combination with GHRPs: When co-administered with a growth hormone releasing peptide (GHRP) such as Ipamorelin or GHRP-2, the short-acting Mod GRF 1-29 provides a synergistic pulse that closely mimics the natural GHRH/ghrelin co-stimulation of GH release.
• Mechanistic studies of GHRH receptor signalling: A short-lived exposure allows precise temporal control of GHRH receptor activation, enabling studies of receptor kinetics, desensitisation, and downstream signalling cascades.
• Studies where somatostatin feedback is relevant: Research examining the interplay between GHRH and somatostatin requires preserved feedback dynamics, which are maintained with the short-acting variant.

CJC-1295 with DAC in the Literature

The albumin-bound variant appears in the published literature where the study design involves:

• Sustained GH and IGF-1 elevation: Studies examining the effects of chronically elevated GH/IGF-1 on body composition, bone density, organ growth, or metabolic parameters.
• GH deficiency models: Studies using hypophysectomised or GH-deficient animal models where the goal is to restore sustained GH/IGF-1 levels rather than to replicate pulsatile physiology.
• Pharmacokinetic studies of albumin-binding peptides: CJC-1295 DAC is a useful model compound for studying the pharmacokinetics of albumin-binding drug delivery systems.

5. Kinetic Consequences for Study Design

The half-life difference is the whole of the practical distinction. A sequence that clears in about thirty minutes gives a GH profile that rises and falls with each exposure, so the published no-DAC studies report their GH endpoints as pulse amplitude and timing, and their IGF-1 endpoints as an integral over repeated pulses. A sequence that remains albumin-bound for days gives a GH profile that does not return to baseline between exposures, so the DAC studies report steady-state levels reached only after several half-lives, and note that measurements taken earlier describe a rising rather than a stable profile.

Those are descriptions of what the literature measures and why. This guide gives no doses, routes, schedules or sampling times, and none should be inferred from it; laboratory reconstitution and storage are covered in the handling and storage guides.

6. Side-by-Side Summary

The table records the study types in which each variant appears in the published literature. It does not rank the variants or recommend one.

7. Combination Research: CJC-1295 with Ipamorelin

The combination of CJC-1295 without DAC with Ipamorelin (a selective GHRP-2 analogue) is one of the most studied growth hormone secretagogue combinations in preclinical research. The rationale is based on the complementary mechanisms of the two compounds: CJC-1295 (Mod GRF 1-29) activates the GHRH receptor, while Ipamorelin activates the ghrelin receptor (GHS-R1a). These two receptor pathways act synergistically to produce a GH pulse that is significantly larger than either compound alone — an effect that has been demonstrated in multiple rodent studies.

The synergistic effect occurs because GHRH and ghrelin receptor activation converge on different intracellular signalling pathways (cAMP and PKC/IP3 respectively) that both contribute to GH secretory granule exocytosis. Co-activation of both pathways produces a supra-additive GH response. For research purposes, this combination is particularly useful when studying the downstream effects of large GH pulses on IGF-1 production, tissue anabolism, or metabolic parameters.

Core Research supplies both CJC-1295 without DAC and Ipamorelin individually, as well as a pre-blended CJC-1295/Ipamorelin combination product for research convenience. For combination research protocols, see our dedicated guide: CJC-1295/Ipamorelin Combination Research Protocol.

Related Guides & Resources